Recommended Tranexamic Acid Dosing for Normal Renal Function
For patients with normal renal function and no contraindications, administer tranexamic acid 1 g IV over 10 minutes as a loading dose, followed by 1 g infused over 8 hours. This regimen is supported by the strongest evidence from large-scale trauma trials and has been adopted across multiple clinical guidelines 1, 2, 3, 4.
Standard Dosing Regimen
The evidence-based dosing protocol consists of:
- Loading dose: 1 g IV over 10 minutes (or 10 mg/kg if weight-based dosing preferred)
- Maintenance infusion: 1 g IV over 8 hours (or 10 mg/kg IV every 8 hours)
- Alternative oral dosing: 1 to 1.5 g orally every 8 to 12 hours 1
This regimen derives from the landmark CRASH-2 trial, which demonstrated a 1.5% absolute reduction in mortality (14.5% vs 16.0%) in trauma patients with significant hemorrhage 2, 3. The dosing has been validated across multiple clinical contexts including trauma, postpartum hemorrhage, and surgical bleeding.
Critical Timing Considerations
Administer tranexamic acid as early as possible, ideally within the first hour after bleeding onset, and absolutely within 3 hours. The benefit decreases by approximately 10% for every 15-minute delay 2. Administration beyond 3 hours shows no benefit and may actually increase mortality from hemorrhage (RR 1.44,95% CI 1.12-1.84) 2.
For postpartum hemorrhage specifically, WHO strongly recommends administration within 3 hours of birth, with a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours 5.
Context-Specific Modifications
Trauma and Severe Bleeding
The standard 1 g + 1 g over 8 hours regimen remains the gold standard 3, 4. Some evidence suggests higher total doses (up to 3 g) may benefit hypotensive patients, though this increases thromboembolic risk 2.
Anticoagulation-Related Bleeding
For patients on oral anticoagulants with severe bleeding, use the same standard dosing (1 g over 10 minutes, then 1 g over 8 hours) or the alternative weight-based regimen of 10 mg/kg IV every 8 hours 1.
Surgical Settings
The FDA-approved indication for hemophilia patients undergoing dental extraction specifies 10 mg/kg IV immediately before the procedure, then 10 mg/kg 3-4 times daily for 2-8 days 6. However, for general surgical bleeding prophylaxis, lower maintenance doses (1 mg/kg/hour) may be adequate 7.
Important Safety Considerations
Do not exceed 4 g total dose - doses above this threshold significantly increase thromboembolic risk (HR 5.33,95% CI 1.94-14.63) 8. The HALT-IT trial used a higher dose regimen (1 g + 3 g over 24 hours) and showed increased VTE risk (0.8% vs 0.4%, RR 1.85) without additional bleeding benefit 1.
Contraindications and Warnings
- Never administer intrathecally - this can cause seizures and cardiac arrhythmias 6
- Avoid in active intravascular clotting 6
- Contraindicated in subarachnoid hemorrhage due to risk of cerebral edema 6
- Infuse no faster than 1 mL/minute to prevent hypotension 6
Thromboembolic Risk
While systematic reviews show no increased risk of stroke, MI, PE, or DVT at standard doses 1, avoid concomitant use with prothrombotic agents (Factor IX concentrates, hormonal contraceptives) 9, 6. The risk-benefit ratio favors treatment in hemorrhagic shock but becomes less favorable in patients without shock 8.
Practical Administration
- Route: Intravenous only (oral formulations available for less acute situations)
- Infusion rate: Maximum 1 mL/minute for IV bolus 6
- Compatibility: Can mix with most IV solutions (electrolytes, dextrose, amino acids) but NOT with blood products or penicillin 6
- Timing: Administer immediately upon recognition of significant bleeding - do not wait for laboratory confirmation of hyperfibrinolysis 4
The evidence consistently supports this dosing across trauma, obstetric, and surgical bleeding contexts, with the critical factors being early administration (within 3 hours) and avoiding excessive total doses (>4 g) that increase thromboembolic complications without additional hemostatic benefit.